OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Hematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Evidence-based indications of platelet-rich plasma therapy	63
Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia	37
Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians	37
The biology and management of dyskeratosis congenita and related disorders of telomeres	36
A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’	33
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia	33
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis	28
Immune thrombocytopenia	25
The spectrum of beta-thalassemia mutations in the 22 Arab countries: a systematic review	23
Complement activation and coagulopathy - an ominous duo in COVID19	22
Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis	22
Avapritinib for Systemic Mastocytosis	20
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases	20
The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas	20
Safety of FLT3 inhibitors in patients with acute myeloid leukemia	19
Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment	18
Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors	18
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond	17
Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?	16
Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies	16
Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma	15
Hematological manifestations and complications of Gaucher disease	15
Hemostatic defects in massive transfusion: an update and treatment recommendations	15
Voxelotor for the treatment of sickle cell disease	15
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia	15

Biomarkers for acute and chronic graft versus host disease: state of the art	14
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies	14
MRI detection of brain abnormality in sickle cell disease	14
Apoptosis targeted therapies in acute myeloid leukemia: an update	14
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development	13
Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients	13
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma	13
Renal disease associated with chronic myeloproliferative neoplasms	12
Screening tools for hereditary hemolytic anemia: new concepts and strategies	12
Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management	12
Copper deficiency, a rare but correctable cause of pancytopenia: a review of literature	11
Exercise and anemia in cancer patients: could it make the difference?	10
Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia	10
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders	10
Targeting CD123 in BPDCN: an emerging field	10
Synovitis in hemophilia: preventing, detecting, and treating joint bleeds	10
Identification and management of fetal anemia due to hemolytic disease	10
Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence	10
Strategies to increase access to basic sickle cell disease care in low- and middle-income countries	9
Immunodeficiency-associated Hodgkin lymphoma	9
Chronic lymphocytic leukemia prognostic models in real life: still a long way off	9
Lived experience experts: a name created by us for us	9
The role of platelets, neutrophils and endothelium in COVID-19 infection	9
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma	9
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding	9
Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia	9
Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection	9
Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review	8
Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner’s perspective	8
CD123-targeted therapy in acute myeloid leukemia	8
Chronic neutropenia: how best to assess severity and approach management?	8
Applying World Health Organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia	8
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura	8
Strategies to overcome the diagnostic challenges of autoimmune hemolytic anemias	8
New directions to develop therapies for people with hemophilia	8
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma	8
Post-COVID-19 hematologic complications: a systematic review	8
Consanguineous marriage and rare bleeding disorders	7
Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review	7
Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings	7
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia	7
Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease	7
An expert spotlight on inferior vena cava filters	7
A critical evaluation of crizanlizumab for the treatment of sickle cell disease	7
Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis	7
The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary	7
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia	7
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis – an option beyond ruxolitinib	7
The relationship between anemia and obesity	7
Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances	7

Hemophilic arthropathy: a teaching approach devoted to hemophilia treaters in under-development countries	7
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice	6
Palliative care for patients with hematologic malignancies: are we meeting patients’ needs early enough?	6
Thrombotic events in children and adolescent patients with SARS-CoV-2 infection: a systematic review with meta-analysis on incidence and management	6
A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma	6
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors	6
The value of the red cell distribution width index versus other parameters in the differentiation between iron deficiency anemia and beta thalassemia trait among children in Mosul, Iraq	6
G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review	6
Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions	6
Hematopoietic stem cell transplantation for classical inherited bone marrow failure syndromes: an update	6
Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?	6
The current role of artificial intelligence in hemophilia	6
Construction of a DLBCL Prognostic Signature Based on Tumor Microenvironment	6
Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?	6
An evaluation of ferric derisomaltose as a treatment for anemia	6
Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients	6
Bispecific antibodies in acute lymphoblastic leukemia therapy	5
Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura	5
CD43 in the malignant flow cytometry laboratory in 2020	5
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts	5
Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting	5
Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia	5
Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy	5
New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia	5
Reducing infectious complications after allogeneic stem cell transplant	5
An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura	5
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders	5
An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes	5
Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions	5
Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies	5
Total knee arthroplasty in hemophilia: lessons learned and projections of what’s next for hemophilic knee joint health	5
Selinexor for the treatment of patients with previously treated multiple myeloma	5
How low risk are low risk myelodysplastic syndromes?	5
Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid	5
Real-world comparison of direct-acting oral anticoagulants and vitamin K antagonists in chronic kidney disease: a systematic review and meta-analysis	5
Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis	5
Secondary erythrocytosis	5
Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review	5
Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines	5
Pain management in people with hemophilia in childhood and young adulthood	5
Voxelotor for the treatment of sickle cell disease in pediatric patients	5